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Background: A computation approach based on integrating high throughput binding affinity comparison and
binding descriptor classifications was utilized to establish the correlation among substrate properties and their
affinity to Breast Cancer Resistant Protein (BCRP). The uptake rates of Mitoxantrone in the presence of various
substrates were evaluated as an in vitro screening index for comparison of their binding affinity to BCRP.
The effects of chemical properties of various chemotherapeutics, such as antiviral, antibiotic, calcium channel
blockers, anticancer and antifungal agents, on their affinity to BCRP, were evaluated using HEK (human embryonic
kidney) cells in which 3 polymorphs, namely 482R (wild type) and two mutants (482G and 482T) of BCRP, have
been identified. The quantitative structure activity relationship (QSAR) model was developed using the sequential
approaches of Austin Model 1 (AM1), CODESSA program, heuristic method (HM) and multiple linear regression
(MLR) to establish the relationship between structural specificity of BCRP substrates and their uptake rates by BCRP
polymorphs.
Results: The BCRP mutations may induce conformational changes as manifested by the altered uptake rates of
Mitoxantrone by BCRP in the presence of other competitive binding substrates that have a varying degree of
affinities toward BCRP efflux. This study also revealed that the binding affinity of test substrates to each polymorph
was affected by varying descriptors, such as constitutional, topological, geometrical, electrostatic, thermodynamic,
and quantum chemical descriptors.
Conclusion: Descriptors involved with the net surface charge and energy level of substrates seem to be the
common integral factors for defining binding specificity of selected substrates to BCRP polymorph. The
reproducible outcomes and validation process further supported the accuracy of the computational model in
assessing the correlation among descriptors involved with substrate affinity to BCRP polymorph. A quantitative
computation approach will provide important structural insight into optimal designing of new chemotherapeutic
agents with improved pharmacological efficacies.
Keywords: Binding affinity, QSAR, BCRP, Polymorph, MitoxantroneBackground
The computational tools intended for quantitative assess-
ment of protein-ligand interactions are based on several
factors including protein-ligand docking, molecular
dynamic simulation and free energy calculations [1]. To
better define the role of binding affinity in forming a
protein-ligand complex, a structural characterization for
putative human off-targets was recently performed on
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reproduction in any medium, provided the oreffects in cancer cells [2]. In this experiment, they
have adapted numerous computational models that
integrated molecular dynamic simulation, free energy
calculations with ligand binding site comparison and
biological network analysis.
There are two integral screening approaches that could
help identify and characterize the substrates and inhibitors
of the efflux proteins and/or transporter system; the mea-
surement of binding affinity and toxicity analysis of
substrate compounds [3]. There was a report that drug resi-
dent time and uptake amount are better correlated with
drug efficacy than the binding affinity [4-6], suggesting that
lead optimization could be efficiently accomplished withtd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methodologies have been proposed for drug-target scree-
ning strategies based on binding affinity [7,8], there are no
efficient computational tools available for the accurate
estimation of the drug uptake profiles from the point of the
molecular structures. In this study, the uptake rates of
Mitoxantrone in the presence of various substrate
compounds were examined as an in vitro screening index
that could help to characterize the binding properties of
chemotherapeutic drugs to tumor cells or efflux proteins.
Breast cancer resistant protein (BCRP) also known as
ABCP or MXR or ABCG2 is a member of transporter
super family ATP binding cassette (ABC) proteins.
BCRP is known to affect the therapeutically available
concentrations of various clinical agents [9-11]. Since
the BCRP effluxes a wide range of structurally diverse
xenobiotic compounds from cells [12], the broad distri-
bution of BCRP not only renders less complete distribu-
tion of drugs but also causes a poor response of cells to
chemotherapeutics [13-15]. BCRP in conjunction with
P-gp expression at target sites affected the pharmacoki-
netic profiles of substrates and inhibitors [16]. Subse-
quently, the therapeutically available concentrations of
certain agents increased in BCRP knock-out animal
models that were highly prone to Mitoxantrone induced
toxicity [17].
The in vitro studies on the BCRP efflux system have
demonstrated that some cell lines displayed erratic efflux
profiles of doxorubicin and rhodamine 123, and these
observations were attributable to 482nd position in the
amino acid sequence consisting of arginine, glycine or
threonine residues which are susceptible to numerous
posttranslational modifications [18-20]. Three poly-
morphs, namely 482R (wild type) and two mutants (482G
and 482T) of BCRP, have been identified, and alterations
in their expressions and functions were reported [21].
Wild-type BCRP and its variants were markedly expressed
in human embryonic kidney (HEK) cells [22].
The present study was intended to establish the rela-
tionships between chemical properties involved with the
uptake rates of structurally diverse substrates and BCRP
polymorphs. To achieve this goal, we have designed the
computational model consisting of numerous molecular
descriptors. The uptake rates of Mitoxantrone by BCRP
were examined in the presence of various pharmacological
classes of ABC transporter inhibitors, such as antiviral
(i.e. Erythromycin, Foscarnet), antibiotic (i.e. Ciprofloxacin,
Febendazole, Novobiocin, Quercitin), calcium channel
blockers (i.e. Verapamil, Diltiazem, Nifedipine, Qunidine),
anticancer (i.e. Mitroxantrone, Acyclovir, FTC, Phenethyl
ITC, Raloxifene, Rodamin 123, Saquinavir, Tamoxifene),
antifungal agents (i.e. Ketoconazole), hormones (i.e., Estra-
diol) and immunosuppressant (Cyclosporin) [16,23]. It was
hypothesized that any changes in uptake rates ofMitoxantrone are due to competitive binding of these
substrates to BCRP.
In the development of a computational model for pre-
diction of structural specificity of substrate compounds
to BCRP, three dimensional structures of the substrates
were built using AMPAC with Graphical User Interface
(Semichem, Shawnee Mission, KS). AMPAC used Austin
Model 1 (AM1) for the quantum mechanical semi-
empirical calculations of interactive energy. CODESSA
can generate the numerical values for molecular descrip-
tors, whereas the heuristic method (HM) preselects
appropriate molecular descriptors. The multiple linear
regression (MLR) is capable of deriving the linear QSAR
based on them. The final outcomes were labeled as a
characterization of compounds using derived properties
X from AM1 calculations and regression with MLR,
using measurements Y as response. The knowledge on
such descriptors that determine substrate specificity to
binding receptors is critical to delineate the drug inter-
action with BCRP polymorphs and the mechanisms
behind their action. The outcomes of this study ultimately
lead us to discover efficient new drugs with enhanced
chemotherapeutic efficacies.
Results and discussion
The uptake rates of Mitoxantrone by HEK cells
The effects of various substrates on the uptake rates of
Mitoxantrone by HEK cells were evaluated to determine
their binding capacity to BCRP polymorphs. The uptake
rates of Mitoxantrone (expressed per mg of protein) in
the presence of various substrates were converted to the
percentage uptake rate of Mitoxantrone in the absence
of the substrates (Figure 1). The transcellular permeation
profiles of the substrate compounds showed a similar
trend to those of the uptake profiles, but statistical sig-
nificance of the latter is much greater than the former.
There are several important findings from this study.
1. Estrogen and tamoxifen did not significantly affect
the Mitoxantrone uptake profiles, which are
consistent with the previous findings [24].
2. Substrate compounds, such as Ciprofloxacin,
Ketoconazole and Verapamil, allow for a greater
Mitoxantrone uptake rate in 482G than 482R. BCRP
substrates with the high binding affinities have
common chemical structures, such as an azole ring
[25], and quarternary nitrogen [26].
3. In HEK 482T, substrate compounds, such as
Caffeine, Diltiazem, Epinephrine, Estradiol,
Raloxifene and Verapamil, did not significantly affect
the uptake rate of Mitoxantrone, whereas in both
482R and 482G, substrate compounds, such as
Foscarnet and Rhodamine 123, did not significantly











































































































































Figure 1 Mitoxantrone uptake by the 482 R, 482 G and 482 T transfected HEK cells in the presence of various substrate compounds.
The data are expressed as mean +/− SD, p < 0.05, each experiment performed in quadruplicate.
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Mitoxantrone in the presence of various substrates are
due to their influence toward BCRP efflux polymorphs.
Although an indirect approach associated with the
uptake rate may not be the best option to predict the
relationship with the chemical structures, the changes in
the uptake rate of Mitoxantrone in the presence of sub-
strate compounds could serve as a valid indicator for the
drug affinity to BCRP.
Relationships between the uptake rates and chemical
properties
I. 482R Polymorphs
The relationships between the uptake rates and the
chemical structures of substrates were analyzed and
quantitatively expressed as the concentration of a sub-
strate required to exert a biological response. As shown
in Table 1, four descriptors, HOMO-1 energy, Max
atomic orbital electronic population, ESP-Max net
atomic charge and average electrophilic reaction index
for a O atom, mainly contribute to the linear relation-
ship profiles in a QSAR model for 482R polymorph
with the experimental coefficient value R2 of 0.9740
(F = 56.17 s2 = 0.024 Q2 = 0.8561: Table 2), which are
indicative of a close correlation among them. As shown in
Figure 2, the prediction power of the test substrates was
also within 5% of the experimental value, which further
corroborated the proposed model.
It was noted that the dynamics of the aromatic cores
and the alkyl tails can affect the electronic properties.The highest occupied molecular orbital (HOMO) and
the lowest unoccupied molecular orbital (LUMO) are
just two of molecular energy levels, and efficient energy
conversion is an integral step in practical applications of
substrates for charge transport and transfer processes
through efflux proteins or transporters.
Another important descriptor seems to be overall net
charge and surface charge of substrates. As the atomic
charge of the molecule increases, the modulation of the
uptake rate of Mitoxantrone decreases (X-axis is expressed
as a negative absolute value), indicating that the charge in
the molecules were inversely correlated with the uptake
rates by BCRP 482R polymorphs. This finding is in a good
agreement with the previous report that ABC transporters
have a greater affinity to positively charged molecules
which serve as an electron accepting functional group [27].
Phenethyl Isothiocyanate (PEITC), which showed a
higher affinity to 482R, has an electropositive property
originated from thiocyanate functional groups which
may contribute to its strong affinity to 482R. On the
other hand, Substrates, such as caffeine, estradiol and
verapamil didn’t significantly affect the uptake rate of
Mitoxantrone by 482R polymorphs.
II. 482G Polymorphs
The results of the study with 482G polymorph were
most properly expressed in a linear QSAR equation
consist of 4 descriptors, which are ESP-Max net atomic
charge, Max SIGMA-PI bond order, Max 1-electron
reaction index for a C atom, and ESP-FPSA-1 Fractional
Table 1 The best linear models computed for 482 R, 482 G and 482 T of BCRP
Type The Best Linear Model
482 R R2=0.9740 F=56.17 s2=0.024 Q2= 0.8561 (4, RANK)
X DX t-test
0 -4.1145e+02 1.7878e+01 23.0141 Intercept
1 1.2538e+01 6.6354e-01 18.8958 HOMO-1 energy
2 2.9607e+02 9.1140e+00 32.4857 Max atomic orbital electronic population
3 -1.0329e+01 5.3540e-01 19.2916 ESP-Max net atomic charge
4 1.7837e+03 2.4776e+02 7.1996 Avg electroph. react. index for a O atom
482 G R2=0.8455 F=82.1 s2=0.0181 Q2= 0.5986 (4, RANK)
X DX t-test
0 -3.5513e+02 1.9119e+01 18.5750 Intercept
1 -1.2124e+03 3.4838e+01 34.8023 ESP-Max net atomic charge 2
2. 0790e+02 6.3673e+00 32.6508 Max SIGMA-PI bond order
3 3.5144e+01 1.6146e+00 21.7656 Max 1-electron react. index for a C atom
4 2.4821e+01 4.9829e+00 4.9812 ESP-FPSA-1 Fractional PPSA (PPSA-1/TMSA)
[Quantum-Chemical PC]
482 T R2=0.8268 F=71.6 s2=0.027 Q2= 0.5617 (5, RANK)
X DX t-test
0 2.0718e+02 4.8027e+01 4.3139 Intercept
1 5.4190e+01 7.7933e+00 6.9535 ESP-Max net atomic charge
2 6.1209e+01 2.6032e+00 23.5132 ESP-Max net atomic charge for a N atom
3 8.9479e+00 6.5221e-01 13.7193 Number of double bonds
4 2.0862e+00 2.3046e-01 9.0521 min(#HA, #HD) [Quantum-Chemical PC]
5 7.9300e-01 1.9317e-01 4.1053 Min e-n attraction for a C-C bond
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the correlation coefficient for the modulated uptake of
R2 of 0.8455 (F = 82.1 s2 = 0.0181 Q2 = 0.5986), as shown
in Tables 1 and 2. The predicted value for the substrate
molecules was also within 5% of the experimental value
as shown in Figure 3. Similar to the results of 482R poly-
morph, it was also demonstrated that affinity of the
482G polymorph to BCRP decreases, as the charge on
the molecule increases. The correlation coefficient
between two variables (i.e., charge and binding affinity)
for 482G polymorph is less significant than that of 482R.
Among substrates, Phenethyl Isothiocyanate (PEITC)
has the highest binding affinity to 482G. The binding
affinity of Rhodamine123 to 482G polymorph is lower
than that to 482R. Febendazole and Riboflavin showed a
low binding affinity to 482G, mainly due to the presence of
multiple double bonds and aromatic rings. Substrates, such
as Rhodamine123 (123%), Estradiol (114%) and Foscarnet
(111%), did not significantly affect the Mitoxantrone uptake
rate by 482R polymorph.
III. 482T Polymorph
As shown in Table 1, a linear QSAR for 482T polymorph
consists of 5 descriptors; ESP-Max net atomic charge,ESP-Max net atomic charge for a N atom, Number of
double bonds, min (#HA, #HD) [Quantum-Chemical PC],
and Min e-n attraction for a C-C bond. The correlation
value for the modulated uptake rate was 0.8268 (F = 71.6,
s2 = 0.027, Q2 = 0.5617) and the predicted power of the
test molecules was within 5% of the experimental out-
comes, indicating that there is a good correlation among
selected parameters. As shown in Figure 3, differing from
the results of 482R and 482G polymorph, there is a
positive relationship between surface charge and bin-
ding affinity; as a charge on the molecule increases, its
binding affinity to 482 T polymorph increases. The results
of this study suggest that the presence of the charged resi-
due significantly affects the affinity of test substrates even
though it does not substantially contribute to the specifi-
city to each BCRP polymorph. The steric factors are likely
to play a vital role in the relationship between substrate
property and binding affinity, even though their contribu-
tion to the binding affinity of substrates to BCRP is much
less than the charged residue.
482T polymorph has a lower affinity towards substrates,
such as Caffeine, Diltiazem, Raloxifene, Quinidine and
Verapamil. Fumitremorgin C (FTC) showed the highest
impact on the uptake rate of Mitoxantrone by 482T,
Table 2 Computed R2 and Q2 values of the linear models
for 482 R, 482 G and 482 T of BCRP
Sets R2 Q2
482C Training set 0.9740 0.8561
Test set 0.9960 0.8506
482G Training set 0.8455 0.5986
Test set 0.9976 0.8336
482T Training set 0.8268 0.5617
Test set 0.9755 0.8438
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species on FTC. Since the side effects of FTC (i.e., neuro-
toxicity) arises from stereo chemical constraints on the
conformation of the diketopiperazine D ring, the
replacement of the proline moiety (E ring) by an
acyclic substituent might allow the adjacent diketopi-
perazine ring to assume a new conformation with the
less charge species that renders the diastereoisomeric
mixtures of FTC analogues less neurotoxic than
native FTC [28,29].
Quercitin, which is known as the most active reactive
oxygen species (i.e., peroxynitrite) scavenger among the
structural analogues of flavonoids, had a significant impact
on the uptake rate of Mitoxantrone in all three poly-
morphs, probably due to the fact that Quercitin has high
resonance and donates electrons on the oxygen atom
even though it lacks nitrogen atoms on the aromatic
ring. It was reported that molecule oxygen atom on
C-4 of C ring of Quercetin carries the largest excess
charge, whereas charge accumulation on the hydroxy
groups at the same ring is not considerably large
[30,31]. On the other hand, estradiol did not affectFigure 2 a The best linear model for 482 R BCRP (R2 = 0.99, F = 460.38
testing data set.the uptake rate of Mitoxantrone in all three poly-
morphs, indicating that estradiol is not a major substrate
for BCRP.
The results of this study underline importance of com-
plement regulatory proteins in the biologic systems that
outline the binding capacity of exogenous compounds
and subsequent their uptake rates.
IV. The model validation process
The Cross Validation process was carried out to confirm
the predicting power of the QSAR model. The error
values of the coefficient computed through QSAR
model were obtained through assessment of percentage
Absolute Relative Error (ARE) using the absolute value
calculation of [(Actual Output - Predicted Output)/
Actual Output].
The experimental and expected values of each com-
pound were plotted for the validation process as shown
in Figures 2b, 4b and 3b for 482R, 482G and 482T,
respectively. The error values for both individual and
combined descriptors were within 10% of the predicted
values (Table 3), indicating that the predicted values
from the linear model are in good agreement with the
experimental values. It was also proved that the QSAR
can accurately predict the effects of various substrates
on the uptake rate of Mitoxantrone based on the
given set of variables. The linear relationships with
the experimental coefficient value (R2) and cross validate
coefficient value (Q2) of 0.9 and 0.85 (Figure 2b), 0.99 and
0.83 (Figure 3b) and 0.97 and 0.84 (Figure 3b) for
482R, 482G and 482T, respectively, are indicative of a
close correlation between experimental values and
calculated values., cross validated R2 = 0.95). b: The validation of the model on the
Figure 3 a The best linear model for 482 T BCRP (R2 = 0.99, F = 238.48, cross validated R2 = 0.99). b: The validation of the model on the
testing data set.
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affinity of substrates to specific receptors or efflux
proteins is not entirely dependent on a particular variable
or an individual group of variables in the relationship, but
it is rather affected by various combinations of variables.
This finding further supported the robustness of the
QSAR approach in predicting the outcome from the
medical database by avoiding a spurious association within
a set of variables. It was also suggested that descriptors
involved with the drug uptake profiles will give new
insights on chemical modifications that can lead to
designing new chemotherapeutic agent with improved
pharmacological properties.To design a pharmacologically active drug for site-
specific activity is a challenging task that begins with
rationally identifying the targets to which that drug binds.
There are a number of computational approaches in
designing efficient therapeutics based on target identifica-
tion and lead optimization. As the specific binding to ac-
tive targets may have a profound impact on the overall
pharmacological activity [32], the effects of a variety
pattern of protein binding reflected in the uptake profiles
by cell membrane on therapeutic efficacy of drugs could
be adapted as a primary screening means. The importance
of protein binding has already been validated by less
specific protein kinase inhibitors which attack tumors
Figure 4 a The best linear model for 482 G BCRP (R2 = 0.99, F = 576.86, cross validated R2 = 0.90). b: The validation of the model on the
testing data set.
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effective to more than one type of cancer therapies.
A thorough understanding of drug binding interactions
and their relationship with the biological activity requires
high-throughput computational biology approaches. Com-
putational techniques that identify competitive binding
substrates and their inhibition range in cellular networks
have been intensively developed, but their scales are very
limited to initial assessment process [6,34]. Moreover, the
qualitative description of the chemical entity currently
available showed a limited predictive power due to the
high dynamic nature of molecular structures and compli-
cated responses from biological systems including
complex efflux pathways. The mathematical modeling
approaches, such as ordinary differential equations
and pi-calculus, have limitations in that they requirea large number of kinetics parameters to simulate the
dynamic behavior of the biological system to which
chemical entities bind [35,36]. Therefore, a functional
dynamic model based on the qualitative descriptors
defined from the competitive uptake profiles is integral for
parameter optimization and dose regimen specification
of new drug entities.
In recent years, major efforts have been placed on iden-
tifying and characterizing ABC transporters. They are
expressed at the major barriers within the body (e.g., intes-
tine, blood–brain barrier, placenta, kidney, and liver), where
they lowered the uptake rate or enhanced the clearance of
drugs [37]. Breast Cancer Resistant Protein (BCRP) is one
of the most recently discovered members of ABC transpor-
ters. BCRP is a homo-dimer and consists of 655 amino
acids containing a nuclear binding domain and a
Table 3 Validation of the uptake rates of Mitoxantrone for the testing set of substrate compounds: Correlation
between the experimental values of testing substrates and their calculated values based on the best linear model for
each polymorph of BCRP
TEST SET 482R 482R 482G 482G 482T 482T
Exp. Uptake value Cal. Uptake value Exp. Uptake value Cal. Uptake value Exp. Uptake value Cal. Uptake value
Acyclovir 212 160 248 230 274 312
Epinephrine 181 188 123 119 115 105
Foscarnet 126 111 111 135 128 115
FumitremorginC 305 361 291 406 327 391
Ketoconazole 270 272 258 266 263 204
PEITC 288 266 313 346 329 355
Quercetin 247 274 252 269 239 288
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ities with bacterial, yeast, insect and other mammalian ABC
transporter proteins [38]. In normal human tissues, BCRP
was detected at higher levels in the placenta and at lower
levels in the brain, prostate, ovary, colon, testis, liver, small
intestine, kidney and heart [22,39]. Among normal tissues,
BCRP is expressed in sycytiotrophoblasts of placenta,
epithelium of small intestine, colon, liver, ducts and lobules
of breast, and haemopoietic stem cells [22,40].
ABC transporters comprise various efflux proteins,
some of which exert abnormal responses to exogenous
compounds due to the presence of polymorphs. Nine
polymorphs have been identified for MDR-1 [41]. In a
clinical trial, ABCG2 polymorphism has a vital role in
delineating the effective dose in chemotherapy [42].
Genetic polymorphism in ABC transporters influences
numerous diseases including hypertension [43], lung
cancer [44] and colon cancer [45]. The mutation of poly-
morphs discovered from human BCRP serves an integral
criterion for the differential affinity of substrates to
BCRP [46]. It was found that the affinity of BCRP to
substrates can be modulated by altering the substrate
specificity of multi-drug transporters. Several BCRP
variants from direct DNA sequencing of the BCRP gene
have been reported [47]. It was also demonstrated that
single nucleotide polymorphisms (SNP) of BCRP pro-
duced individual variations in the pharmacokinetics and
toxicity profiles of BCRP substrates. BCRP G34A (Val12-
Met) and C421A (Gln141Lys) polymorphisms occurred
at high frequency in most ethnic populations and have
been associated with the expression and activity of BCRP
protein [48]. It has distinctive features including racial
differences; for instance, BCRP V12M, Q141K, P269S
and Q126Stop were detected in Korean at frequencies of
23, 28, 0.2 and 1.9%, respectively [49].
This study was undertaken to define various physico-
dynamic and chemical properties of substrates to BCRP
polymorphs and elucidate the rationales behind their
efficacies. The structurally diverse compounds wereevaluated for elucidation of the BCRP polymorph
mediated uptakes and establishment of the relationships
with their molecular structures. The results of this study
suggested that the chemical properties of exogenous
compounds significantly influence BCRP polymorphs
mediated uptake rate. All the compounds tested in this
study are either substrates or inhibitors of at least one of
BCRP polymorphs. The analysis on the chemical proper-
ties of the substrates based on the combining AMPAC/
CPDESSA approach could help us to identify integral
descriptors that should be mirrored by interactions with
receptor proteins [50].
In this study, the consistent appearance of surface charge,
electrophilic reactivity indices and molecular orbital energy
descriptors obtained from the sets of chemotherapeutic
substrate compounds supported the proven concept that
charged electrophiles with the high energy level affected
the affinity to BCRP polymorphs. The quantum chemical
descriptors of the substrates, such as atomic orbital elec-
tronic population and bond order, also significantly contrib-
ute to its affinity to BCRP polymorph. It is known that the
docking analysis of descriptors provides a qualitative repre-
sentation of ligand and protein interactions in the QSAR
model, even though the selection of docked conformations
is often complicated due to its sensitivity to the scoring
function. The results of this study demonstrate that sub-
strate compounds containing net charged radicals can acti-
vate efflux proteins or peptides in the complement system.
There is also a close correlation between descriptors and
molecular weight, especially for bulky groups. The steric
contour analysis indicates that the addition of bulky groups
in the active region reduces the binding affinity.
It is possible that subjects with these polymorphisms may
have different levels of single nucleotide polymorphisms
(SNP) expression level and cellular localization and, conse-
quently, varying degrees of efflux capability to model
compounds [51]. Further studies are needed to determine
which level and sites of SNP mainly contribute to the speci-
ficity of BCRP bindings. The findings in this study provide
Table 4 The changes in the uptake rate of Mitoxantrone in 482 R, 482 G and 482 T BCRP transfected HEK cell line in
the presence of substrate compounds
Changes in Uptake of Mitoxantrone (cm/sec: %)
482R 482G 482T
Mitoxantrone 23.71 (100%) 27.43 (100%) 25.92 (100%)
Training Set Caffeine 29.64 (125%) 41.42 (151%) 46.28 (140%)
Ciprofloxacin 57.38 (242%) 63.91 (233%) 45.88 (177%)
Cyclosporin 70.18 (296%) 66.93 (244%) 63.76 (246%)
Diltiazem 55.95 (236%) 59.52 (217%) 32.40 (125%)
Erythromycin 37.93 (160%) 48.00 (175%) 50.02 (193%)
Estradiol 29.87 (126%) 31.27 (114%) 26.70 (103%)
Febendazole 30.82 (130%) 34.83 (127%) 38.36 (148%)
Ketoconazole 64.50 (272%) 70.22 (256%) 68.17 (263%)
Nifedipine 38.17 (161%) 42.52 (155%) 38.36 (148%)
Novobiocin 56.90 (240%) 77.35 (282%) 71.02 (274%)
Quinidine 38.64 (163%) 41.97 (153%) 33.17 (128%)
Raloxifene 46.47 (196%) 55.95 (204%) 23.58 (91%)
Rhodamine 123 44.57 (188%) 33.74 (123%) 43.02 (166%)
Riboflavin 41.25 (174%) 35.92 (131%) 36.80 (142%)
Saquinavir 46.00 (194%) 57.33 (209%) 72.83 (281%)
Tamoxifene 31.30 (132%) 38.67 (141%) 40.95 (158%)
Verapamil 29.87 (126%) 58.42 (213%) 31.36 (121%)
Test Set Acyclovir 50.26 (212%) 66.91 (244%) 68.95 (266%)
Epinephrine 42.91 (181%) 33.73 (123%) 24.89 (115%)
Foscarnet 29.87 (126%) 30.45 (111%) 33.17 (128%)
FumitremorginC 26.76 (305%) 79.82 (291%) 84.75 (327%)
Ketoconazole 64.02 (270%) 70.77 (258%) 68.17 (263%)
PEITC 68.28 (288%) 85.85 (313%) 85.27 (329%)
Quercetin 58.56 (247%) 69.12 (252%) 61.95 (239%)
The data are expressed as mean +/− SD, p < 0.05, each experiment performed in quadruplicate.
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working mechanisms are closely correlated with substrate
or inhibitor properties against BCRP polymorphs. The
results of this study can lead to detailed constitutional
descriptors that can be directly translated to a chemical
structure, such as connectivity indices and descriptors
describing substitution patterns. It is possible to combine
and translate calculated properties of descriptors into a new
chemical/pharmaceutical entity through the visualization
process by the contour map and an analyzing tool like
GaussView program (GaussView 3.07: Gaussian Inc.,
Wallingford, CT). It is certain that numerous training
compounds need to span through the model fitting
techniques, addressing not only finding a fit, but also
the predictive feature of the fit. While the outcomes of
this study have not directly steered us to a new com-
pound, they have helped us to identify important
structural insight into optimal designing of newchemotherapeutic agents. Recently, a drug class called
poly ADP ribose polymerase (PARP) inhibitors that tar-
gets cancers caused by BRCA mutations have shown
promise in clinical trials treating breast cancer [52].
Conclusions
In summary, the chemotherapeutic effects of the known
substrates were classified based on their binding affinity
to BCRP. The computational approach with the sequen-
tial approaches of Austin Model 1 (AM1), CODESSA
program, heuristic method (HM) and multiple linear
regression (MLR) was performed to derive QSAR model
and its predictive power was validated. The BCRP muta-
tions may induce conformational changes as manifested
by the altered uptake rates of Mitoxantrone by BCRP in
the presence of other competitive binding substrates
that have a varying degree of affinities toward BCRP ef-














































































































































































































Figure 5 Structures of Mitoxantrone and substrates tested in this study.
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http://journal.chemistrycentral.com/content/7/1/23structural approach will help the scientists identify the
best compound and its linear dose range with improved
pharmacological efficacy, eliminating the need to per-
form multiple assays over a wide range of concentra-
tions in defining the binding affinity and uptake rates.Methods
HEK (human embryonic kidney) cell lines transfected
with each polymorph (i.e., 482R, 482G and 482T) were
kindly donated by NIC (NIH, Bethesda, MD) [53].
The minimum essential medium was purchased from
Table 5 Descriptors used in this study for identifying the
best linear model
Class Name of Descriptors
Constitutional Number of double bonds
Number of aromatic bonds
Number of Oxygen atoms
Average distance sum connectivity index
ESP-RNCS: Relative negative charged SA
(SAMNEG*RNCG)
ESP-RPCS Relative positive charge SA (QMPOS/QTPLUS)
[Zefirov’s PC]
WPSA3 weighted PPSA (PPSA3*TMSA/1000)
[Zefirov's PC]




Electrostatic Max partial charge
Max partial charge for a hydrogen atom
Max partial charge for a carbon atom
Quantum
Chemical
Max atomic orbital electronic population
ESP-Max net atomic charge
Avg electroph. react. index for a O atom
Max 1-electron react. index for a C atom
Max SIGMA-PI bond order
ESP-Max net atomic charge
ESP-Max net atomic charge for a N atom
min(#HA, #HD) [Quantum-Chemical PC]
Min e-n attraction for a C-C bond
Min e-n attraction for a C-H bond
HOMO-1 energy (Molecular orbital related)
LUMO + 1 energy (Molecular orbital related)
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http://journal.chemistrycentral.com/content/7/1/23ATCC (Manassas, VA). Penicillin, Streptomycin, and
Geneticin were purchased from Invitrogen (Carlsbad, CA).
Radioactive Mitoxantrone was obtained from American
Radiolabelled Inc (St Louis, MO). All other chemicals
and testing compounds were obtained from Sigma
(St Louis, MO).
Cell culture preparation
HEK cell lines transfected with 482R, 482G and 482T
plasmids were grown in the minimum essential medium
supplemented with 10% FBS, 50 IU/ml penicillin, 50 μg/ml
streptomycin, 4 mM L-glutamine and 100 nM Geneticin.
Cells were incubated in 75 mm2 plastic culture flasks at
37°C supplemented with 5% CO2/95% air. BCRP
expression in HEK cells was confirmed by RT-PCR
using the method previously described [54].A drug uptake study
HEK cells were trypsinized and loaded in 24 well plates
at a seeding density of 2 × 105 cells per well. Cell viability
was maintained by providing a fresh medium every other
day until they reached confluence. Cells were exposed
with radioactive Mitoxantrone (~100 μM) in the presence
or absence of various inhibitors at specific concentrations
or 10 μM Fumitremorgin C (FTC) (as a positive control)
at 37°C for 5 min. The drug uptake process was stopped
by washing the cells with 1 ml of ice-cold DPBS for 3
times, followed by lysis with the Triton X/0.1 M NaOH
solution. A cell digest (100 μl) was taken and diluted to 5
ml with 30% Scintisafe™ (Fisher Scientific, NJ). The
cumulative amount of Mitoxantrone in diluted samples
was determined using Beckman Coulter Counter and
expressed as the percentage amount of the control.
Mitoxantrone accumulation was normalized for cellu-
lar protein and presented as the percentage of the
control, where the control represents cells treated
with Mitoxantrone in the absence of any inhibitors.
Data were expressed as mean +/− SD, p < 0.05 and by
one way ANOVA.A drug permeability study
HEK cell lines were prepared as described previously
[54]. After confluence was achieved, the TEER value of
cells was measured to verify the presence of tight junction.
The growth medium was replaced and washed with PBS.
The radioactive Mitoxantrone (~100 μM) in the presence
or absence of inhibitors was added on the basolateral side
of the transwells. The samples were collected from the
apical side at predetermined time intervals for up to 120
min. Apparent drug permeability (Papp) value was calcu-
lated using the formula Papp = (dQ/dt)/(A x D0), where
(dQ/dt) is the linear appearance rate of drug in the apical
side, A is the cross-sectional area of the Transwell insert
and D0 is the initial concentration of the compound in the
baso-lateral compartment [55]. The experiment was
repeated for 4 times for each inhibitor (N = 4).The selection of datasets
As shown in Table 4, the substrates selected according to
the different pharmacological categories were evaluated
for their effects on the flux rates of Mitoxantrone. The ex-
perimental sets (25) were divided into 18 training sets and
7 test sets (i.e., for validation purpose). The structures of
the substrates in the training set are shown in Figure 5.
The uptake rates for Mitoxantrone or those in the
presence of the substrates obtained from the experi-
mental transport study were considered to be directly
proportional to the affinity and/or permeation rate of
drugs with BCRP.
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This approach was intended to select the most suitable
descriptors among the descriptor sets for defining binding
specificity of each polymorph. Three dimensional
structures of the substrates were built using AMPAC
with Graphical User Interface (Semichem, Shawnee
Mission, KS) [56]. For structural classification of
descriptors, AMPAC used Austin Model 1 (AM1),
which is the Hamiltonian widely utilized in the
quantum mechanical semi-empirical calculations of
interactive energy. AM1 achieved energy minimization
of the gradient norm (0.05 kcal/mol) using 20 simplex
iterations followed by 1000 steps of Powell minimization
[57]. CODESSA (Comprehensive Descriptors for Structural
and Statistical Analysis; Semichem, Shawnee Mission, KS)
is an advanced, full featured Quantitative Structure/Activity
Relationship (QSAR) program that connects information
from AMPAC to experimental data [58]. CODESSA prese-
lects each subset of structure descriptors, which include
constitutional, topographical, geometrical, electrostatic,
thermodynamic and quantum chemical properties, as
shown in Table 5. CODESSA can generate the numerical
values for up to 600 molecular descriptors which can be
used for the regression analysis [59].
The heuristic method (HM) preselected appropriate
molecular descriptors and derived the linear QSAR
model based on them. Those descriptors that exist for
all molecules in the training set were included, whereas
those descriptors whose values did not vary throughout
the training set were excluded from the regression. The
number of descriptors in the final QSAR models was
usually less than one third of the number of molecules
in the data set [60]. HM allows us to obtain the best
QSAR based on F and t test values, which were set in
such way that descriptors having more than 0.99 and
less than 0.8 correlations were excluded as they may
generate an over-optimistic regression.
Molecular descriptors selected by the heuristic method
(HM) in CODESSA were used as inputs to perform mul-
tiple linear regression (MLR), which is the simplest
method that builds a single regression equation for a given
data set. For each regression analysis, the goodness of fit
was evaluated by examining the number of molecules (N),
coefficient of determination (r2), cross-validated standard
error (Q2) and value of the F-statistic (F). The Q2 value
obtained through the leave-one-out algorithm (LOO)
cross-validation procedure reflects the stability of the
model through perturbation of the regression coefficients
with the acceptability criterion of 0.5 in most CoMFA
studies [61].
The model validation process
The linear QSAR model was cross validated using the
error values acquired in the prediction process [62]. Tooptimize the validation outcomes, a relationship between
the experimentally obtained values and computed uptake
rates from the test set was established using the heuristic
method. The expected values for each compound were
calculated and plotted to elucidate their correlations
with the experimental values.
Each descriptor was assigned a number through the
web based random number generator (www.random.org)
for cross validation. Individual descriptors were sequen-
tially incorporated into the regression process to monitor
the error value. The following two-fold cross-validation
scheme was implemented.
1. The experimental data (25) were divided into 2
subsets; 18 training sets and 7 test sets for the model
validation.
2. The data from the selected subsets were categorized
into the descriptors listed in Table 5.
3. The odd ratio for each descriptor was calculated to
find the most potential contributors to binding
property with defined risk weights.
4. The significance of the final regression is determined
by comparing prediction Absolute Relative Errors
(AREs) which are obtained using the absolute value
of [(Actual Output - Predicted Output)/Actual
Output] to the test subset. An estimated p value less
than 0.05 was considered to be significant for the
consistency of the model. The model with the lowest
prediction error generated through the cross
validation process was chosen to represent the best
outcome for each BCRP polymorph.
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